Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 430-380-7 | CAS number: 445409-27-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted according to OECD Guideline under GLP conditions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- thymidine kinase, TK +/-, locus of the L5178Y mouse lymphoma cell line
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix
- Test concentrations with justification for top dose:
- Experiment 1: 0, 5, 10, 20, 40, 60 ug/ml (4hr exposure without S9 activation)
Experiment 1: 0, 10, 20, 40, 80, 160 ug/ml (4hr exposure with S9 activation)
Experiment 2: 0, 2.5, 5, 10, 20, 30, 40 ug/ml (24 hr exposure without S9 activation)
Experiment 2: 0, 20, 40, 80, 160, ug/ml (24 hr exposure with S9 activation) - Vehicle / solvent:
- DMSO
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- Positive controls:
- yes
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- Migrated to IUCLID6: at 400 and 150 ug/ml for Experiment 1 and 2, respectively (without activation)
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- Migrated to IUCLID6: at 2 and 1 ug/ml in Experiments 1 and 2, respectively (with activation)
- Evaluation criteria:
- The normal range for mutant frequency per survivor is 50 -200 x 10(-)6 for the TK +/- locus in L5178Y cells at this laboratory. Vehicle controls must be within ranges, although minor errors in cell counting and dilution or exposure to the metabolic activation system may cause this to be slightly elevated. Experiments where the vehicle control values are markedly greater than 200 x 10(-)6 mutant frequency per survivor are not normally acceptable and will be repeated. Positive controls should give significant increases in mutant frequency per survivor over the negative controls or at least a three to five fold but preferably 10 fold difference.
For the test material be considered to give a significant result, two or more of the following criteria must be met: A greater than three fold increase in the mutant frequency per survivor over the negative control value; a dose-related increase in the mutant frequency per survivor; an increase in the absolute number of mutants. The test result may be reported as equivocal if only one of the above criteria are met. Small statistical increases designated by the UKEMS statistical package will be reviewed using the above criteria and may be disregarded at the Study Director's discretion. - Statistics:
- Calculation of the % Relative Suspension Growth (RSG) was performed along with Calculation of the Plating Efficiency (P.E.). The Calculation of Mutant Frequency was determined. The experimental data were analysed using a dedicated computer program which follows the statistical guidelines recommended by UKEMS.
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Experiment 1: There was evidence of toxicity following exposure to the test material in both the presence and absence of metabolic activation, as indicated by the decrease in % RSG and RTG values. Optimum levels of toxicity were not achieved in the absence or presence of metabolic activation due to the steep toxicity of the test material. The toxicity observed at 60 ug/ml in the absence of metabolic activation exceeded the upper acceptable limit of 90%, therefore., this dose was excluded from the statistical analysis. The excessive toxicity observed at 80 ug/ml in the absence of activation and 240 ug/ml in the presence of activation resulted in these dose levels not being plated for viability or TFT resistance. Vehicle and positive controls were within normal limits. The test material did not induce any statistically significant or dose related (linear trend) increases in the mutant frequency x 10(-)6 per viable cell in either the presence or absence of metabolic activation. No precipitate of the test material was observed at any dose level.
Experiment 2: There was evidence of a dose-related reduction in %RSG and RTG values in cultures dosed with the test material in both of the exposure groups. There was no evidence of a reduction in Day 2 (%V) viability, therefore, indicating that no residual toxicity occurred in either the absence or presence of metabolic activation. The excessive toxicity observed at 200 ug/ml and above in the presence of metabolic activation resulted in these dose levels not being plated out for viability or TFT resistance. Both positive controls induced acceptable reductions in both the %RSG value and Day 2 (%V) viabilities and RTG values. Vehicle and positive controls were within normal limits. The test material did not induce any statistically significant or dose related increases in the mutant frequency in either the presence or absence of metabolic activation. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
In an OECD 476 study Molyvan 855 did not induce any toxicologically significant increases in the mutant frequency at the TK +/- locus in L5178Y cells and is therefore considered to be non-mutagenic under the conditions of the test.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
In vitro bacterial mutation:
Key study
In an OECD 471 and OECD 472 study, conducted according to GLP, Molyvan 855 is negative for bacterial reverse mutation in S. typhimurium strains TA 1535, TA 1537, TA 98 and TA 100, and E. coli WP2 uvr A, with and without metabolic activation (S-9 mix). Molyvan 855, therefore, is considered non-mutagenic in bacterial cells. (Safepharm, 1997)
Supporting study
In an OECD 471 study, conducted according to GLP, Molyvan 855 is negative for bacterial reverse mutation in S. typhimurium strains TA 1535, TA 1537, TA 98 and TA 100 and TA 1538, with and without metabolic activation (S-9 mix). Molyvan 855, therefore, is considered non-mutagenic in bacterial cells. (Microbiological Associates, 1995)
In vitro Chromosome Aberration:
Key study
In an OECD 473 study, conducted according to GLP, Molyvan 855 (oil free) did not induce a toxicologically significant increase in the frequency of cells with chromosome aberrations or polyploid cells in either the presence or absence of liver enzyme metabolizing system, Molyvan 855 (oil free) is therefore considered to be non-clastogenic to human lymphocytes in vitro (Safepharm, 1998).
In vitro mutation in mammalian cells:
Key study
In an OECD 476 study Molyvan 855 did not induce any toxicologically significant increases in the mutant frequency at the TK +/- locus in L5178Y cells and is therefore considered to be non-mutagenic under the conditions of the test.(Safepharm, 2004)
Justification for selection of genetic toxicity endpoint
OECD, GLP study.
Justification for classification or non-classification
In accordance with Regulation No 1272/2008 Table 3.5.1, based on available data on Molyvan 855 is not classified for genotoxicity according to CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.